170 Combination of a Nasal Antihistamine Olopatadine and A Leukotriene Receptor Antagonist Montelukast Sodium for the Treatment of Seasonal Allergic Patients not Currently Controlled on Monotherapy Intranasal Antihistamine or a Leukotriene Receptor Antagonist

BACKGROUND: For seasonal Allergic Rhinitis (SAR) patients that remain symptomatic on an intranasal antihistamine, Olopatadine or a leukotriene receptor antagonist Montelukast sodium, the combination of intranasal antihistamine with a leukotriene antagonist Montelukast sodium may provide additional efficacy in sub-optimally controlled Seasonal Allergic Rhinitis Patients. METHODS: In this open 8-week trial 40 patients with symptomatic SAR currently using Olopatadine 1330 mcg/nostril or Montelukast sodium, 10 mg p.o daily were randomized to receive the combination Olopatadine 1330 mcg/nostril BID + Montelukast sodium, 10 mg p.o QD. The end points of the trial include: rhinomanometry, nasal symptom score (composite score of nasal congestion, rhinorrhea, sneezing, post nasal drip, and nasal itching) and flexible rhinopharyngolaryngoscopy examination. RESULTS: Mean efficacy measurements at the end of the 8-week trial revealed significant improvements in all parameters examined in the combination treatment group compared to baseline measurements. CONCLUSIONS: In conclusion, the combination nasal Olopatadine plus Montelukast orally is more effective than monotherapy nasal Olopatadine or Montelukast. It appears that in the combination treatment Olopatadine and Montelukast sodium, the primary end points (rhinomanometry and symptom scores) are significantly improved.